Skip to content
10-Q

Quarterly Report

CATALENT PHARMA SOLUTIONS, INC.

0001416083-13-000007

← back to feed
Filed
May 13, 2013 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2013 · May 1, 2013 100 sh
Capex Q3 2013 · Mar 31, 2013 $84.8M
Capex restated Q3 2013 · Mar 31, 2012 $67.6M
Long Term Debt Q3 2013 · Mar 31, 2013 $2.65B
Long Term Debt Q3 2013 · Jun 30, 2012 $2.64B
Stockholders Equity Q3 2013 · Mar 31, 2013 −$417.4M
Stockholders Equity Q3 2013 · Jun 30, 2012 −$350.7M
Current Liabilities Q3 2013 · Mar 31, 2013 $389M
Current Liabilities Q3 2013 · Jun 30, 2012 $439.3M
Current Assets Q3 2013 · Mar 31, 2013 $631.6M
Current Assets Q3 2013 · Jun 30, 2012 $704.7M
Total Assets Q3 2013 · Mar 31, 2013 $3.02B
Total Assets Q3 2013 · Jun 30, 2012 $3.14B
Revenue Q3 2013 · Mar 31, 2013 $447M
Revenue Q3 2013 · Mar 31, 2013 $1.3B
Revenue Q3 2013 · Mar 31, 2012 $441.3M
Revenue Q3 2013 · Mar 31, 2012 $1.22B
Operating Cash Flow Q3 2013 · Mar 31, 2012 $85.8M
Cash And Equivalents Q3 2013 · Mar 31, 2012 $135.9M
Cash And Equivalents Q3 2013 · Jun 30, 2011 $205.1M
Sga Expense restated Q3 2013 · Mar 31, 2012 $90.8M
Sga Expense restated Q3 2013 · Mar 31, 2012 $242.3M
Net Income Q3 2013 · Mar 31, 2012 −$9.2M
Net Income Q3 2013 · Mar 31, 2012 −$2.2M
Operating Income restated Q3 2013 · Mar 31, 2012 $52.8M
Operating Income restated Q3 2013 · Mar 31, 2012 $150.1M
Gross Profit restated Q3 2013 · Mar 31, 2012 $148.5M
Gross Profit restated Q3 2013 · Mar 31, 2012 $393.1M
Cost Of Revenue restated Q3 2013 · Mar 31, 2012 $292.8M
Cost Of Revenue restated Q3 2013 · Mar 31, 2012 $823.4M